Zobrazeno 1 - 10
of 226
pro vyhledávání: '"HISATO KAWAKAMI"'
Autor:
Takashi Oshima, Sachiko Yamamoto, Hisato Kawakami, Tomoki Makino, Akihito Kawazoe, Toshiki Masuishi, Takahiro Tsushima, Motohiro Hirao, Masahiro Tsuda, Kaori Hino, Noboru Yamamoto, Hiroki Hara, Shota Kaname, Daiko Matsuoka, Yohei Otake, Keisuke Yasuda, Takao Takase, Shuya Takashima, Taro Semba, Akira Ooki
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-7 (2024)
Abstract Background Esophageal cancer is one of the most common types of cancer in Japan. Herein, we report the efficacy and safety of E7389-LF plus the immune checkpoint inhibitor, nivolumab, from the esophageal cancer cohort of the phase 2 part of
Externí odkaz:
https://doaj.org/article/7dbdc5c5725f466f9c680a126d352047
Autor:
Tadayoshi Hashimoto, Yoshiaki Nakamura, Yoshito Komatsu, Satoshi Yuki, Naoki Takahashi, Naohiro Okano, Hidekazu Hirano, Koushiro Ohtsubo, Takashi Ohta, Eiji Oki, Tomohiro Nishina, Hisateru Yasui, Hisato Kawakami, Taito Esaki, Nozomu Machida, Ayako Doi, Shogen Boku, Toshihiro Kudo, Yoshiyuki Yamamoto, Akiyoshi Kanazawa, Tadamichi Denda, Masahiro Goto, Naoko Iida, Hiroshi Ozaki, Taro Shibuki, Mitsuho Imai, Takao Fujisawa, Hideaki Bando, Yoichi Naito, Takayuki Yoshino
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-10 (2024)
Abstract Background While advanced gastrointestinal stromal tumors (GISTs) are primarily treated with tyrosine kinase inhibitors (TKIs), acquired resistance from specific mutations in KIT or PDGFRA frequently occurs. We aimed to assess the utility of
Externí odkaz:
https://doaj.org/article/8d89e02235024fa88d2552871e8438cb
Autor:
Ken Kato, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih‐Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Tomoki Makino, Mariela Blum Murphy, Carlos Amaya‐Chanaga, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Yuko Kitagawa, Jaffer Ajani
Publikováno v:
Cancer Medicine, Vol 13, Iss 9, Pp n/a-n/a (2024)
Abstract Background First‐line nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit versus chemotherapy in previously untreated patients with advanced esophageal squamous cell carcino
Externí odkaz:
https://doaj.org/article/59c4231e83f941f6a4719927e06f1ef1
Autor:
Satoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, Hiroya Taniguchi, Hideaki Bando, Manabu Shiozawa, Tomohiro Nishina, Hisateru Yasui, Yoshinori Kagawa, Naoki Takahashi, Tadamichi Denda, Taito Esaki, Hisato Kawakami, Hironaga Satake, Atsuo Takashima, Nobuhisa Matsuhashi, Takeshi Kato, Chiharu Asano, Yukiko Abe, Shogo Nomura, Takayuki Yoshino
Publikováno v:
Cancer Medicine, Vol 12, Iss 18, Pp 18702-18716 (2023)
Abstract Background Several biomarkers have been established for metastatic colorectal cancer (mCRC). We investigated whether plasma angiogenesis factors could predict the efficacy of biologics combined with chemotherapy in first‐line (1L) treatmen
Externí odkaz:
https://doaj.org/article/3ebebc37f7d94a9b970dc82f9c2f0539
Autor:
Naoki Takahashi, Hiroki Hara, Kengo Nagashima, Kenro Hirata, Toshiki Masuishi, Toshihiko Matsumoto, Hisato Kawakami, Kentaro Yamazaki, Shuichi Hironaka, Narikazu Boku, Kei Muro
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Trifluridine/tipiracil (FTD/TPI) prolongs survival in the third- or later-line treatment for advanced gastric cancer (GC), esophagogastric junction (EGJ) adenocarcinoma, and colorectal cancer. While single-arm phase II trials show
Externí odkaz:
https://doaj.org/article/7e4e091163904bb1a0330ed3bafd6354
Autor:
Chihiro Sato, Hisato Kawakami, Ryo Tanaka, Hironaga Satake, Kentaro Inoue, Yutaka Kimura, Junya Fujita, Ryohei Kawabata, Yasutaka Chiba, Taroh Satoh, Kazuhiko Nakagawa
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Adjuvant S-1 monotherapy is the standard of care for stage II gastric cancer (GC) after curative resection in Japan, but its efficacy for microsatellite instability–high (MSI-H) tumors has remained unknown. Among a multi-institutional coho
Externí odkaz:
https://doaj.org/article/530edf29753342e095c74eb7211e943c
Autor:
Fortunato Ciardiello, Yung‐Jue Bang, Andrés Cervantes, Mikhail Dvorkin, Charles D. Lopez, Jean‐Philippe Metges, Antonio Sánchez Ruiz, Mariona Calvo, Andrew H. Strickland, George Kannourakis, Kei Muro, Hisato Kawakami, Jia Wei, Christophe Borg, Zhaoyin Zhu, Neal Gupta, Robert J. Pelham, Lin Shen
Publikováno v:
Cancer Medicine, Vol 12, Iss 12, Pp 13145-13154 (2023)
Abstract Background Poly (ADP‐ribose) polymerase (PARP) inhibitors (PARPi) are approved for the treatment of various solid tumors. In gastric cancer, genes commonly harbor mutations in the homologous recombination DNA repair pathway, potentially in
Externí odkaz:
https://doaj.org/article/4b2f01f4e75d4aedaab63e873f6aa1b0
Autor:
Takayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Zev Wainberg, Elena Elez, Javier Rodriguez, Marwan Fakih, Fortunato Ciardiello, Kapil Saxena, Kojiro Kobayashi, Emarjola Bako, Yasuyuki Okuda, Gerold Meinhardt, Axel Grothey, Salvatore Siena, DESTINY-CRC01 investigators
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prio
Externí odkaz:
https://doaj.org/article/b78d3fdfa83149b6a91ce6f79897ff81
Autor:
Chiaki Inagaki, Hisato Kawakami, Daichi Maeda, Daisuke Sakai, Shinya Urakawa, Kentaro Nishida, Toshihiro Kudo, Yuichiro Doki, Hidetoshi Eguchi, Hisashi Wada, Taroh Satoh
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract To assess the potential clinical utility of cell-free DNA (cfDNA)-based biomarkers for identifying gastric cancer (GC) patients who benefit from nivolumab. From 31 GC patients treated with nivolumab monotherapy (240 mg/body, Bi-weekly) in 3r
Externí odkaz:
https://doaj.org/article/ecf4d4d29edc41ecacfb02945d3c66d1
Autor:
Takashi Kurosaki, Kenji Chamoto, Shinichiro Suzuki, Hiroaki Kanemura, Seiichiro Mitani, Kaoru Tanaka, Hisato Kawakami, Yo Kishimoto, Yasuharu Haku, Katsuhiro Ito, Toshiyuki Sato, Chihiro Suminaka, Mami Yamaki, Yasutaka Chiba, Tomonori Yaguchi, Koichi Omori, Takashi Kobayashi, Kazuhiko Nakagawa, Tasuku Honjo, Hidetoshi Hayashi
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionThe clinical relevance of soluble forms of programmed cell death-1 (sPD-1) and programmed cell death-ligand 1 (sPD-L1) remains unclear. We here investigated the relation between the efficacy of PD-1 blockade and pretreatment plasma levels
Externí odkaz:
https://doaj.org/article/ca0552f7ccdf42e3ad9e80f1d87a4c8b